Pediatric status epilepticus: Stepwise management with timelines (benzodiazepine, then second-line such as levetiracetam, phenytoin or valproate), refractory SE, and workup.
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
"status epilepticus" AND pediatric
Searching the Web
pediatric status epilepticus treatment guideline benzodiazepine levetiracetam phenytoin valproate dosing timeline
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC10343462/
Pediatric convulsive status epilepticus: stepwise management
Treat any convulsive seizure lasting 5 minutes or recurrent seizures without recovery of consciousness as status epilepticus (SE). For generalized convulsive SE, the operational treatment time is 5 minutes. Management of resuscitation, seizure termination, and investigation occurs simultaneously.
This is an emergency/PICU algorithm. Use local pediatric dosing protocols, weight-based medication charts, and early pediatric neurology/PICU support.
| Time from seizure onset | Priority and actions |
|---|---|
| 0-5 min | ABCDE, position safely, suction, oxygen, cardiorespiratory monitoring, bedside glucose, IV or IO access. |
| 5-10 min | Give an adequate benzodiazepine promptly. If no IV access, use IM/intranasal/buccal midazolam. |
| 10-20 min | If still convulsing after adequate benzodiazepines, load one second-line antiseizure medication: levetiracetam, fosphenytoin/phenytoin, or valproate. Do not wait for the full workup. |
| 20-40 min | Ongoing clinical or electrographic seizures after a benzodiazepine plus one appropriate second-line agent = refractory SE. Intubate if needed, transfer/manage in PICU, initiate continuous EEG, and use an anesthetic infusion. |
| >24 h despite anesthetic therapy, or recurrence during anesthetic reduction | Super-refractory SE. Requires neurocritical care and an expanded cause-directed evaluation. |
For tonic-clonic SE, the International League Against Epilepsy uses 5 minutes as the point at which treatment should begin; longer duration increases difficulty of control and risk of systemic complications.
1. Immediate stabilization: 0-5 minutes
ABCDE and monitoring
- Protect from injury, place in lateral position if feasible, suction secretions.
- Give high-flow oxygen if hypoxemic, support ventilation with bag-mask ventilation if required.
- Place continuous pulse oximetry, ECG, noninvasive blood-pressure, and capnography monitoring if available.
- Obtain IV access. If this is not rapidly possible, establish intraosseous access.
- Check a point-of-care glucose immediately.
- Do not delay antiseizure treatment to obtain blood samples or imaging.
Children with continuing convulsions are at risk of hypoventilation, aspiration, respiratory depression from medications, and circulatory instability. Rosen’s emphasizes early airway/ventilation support and rapid IV or IO access in actively seizing children.
Correct immediately reversible causes
- Hypoglycemia: give dextrose per local pediatric protocol. One emergency-medicine reference uses D10W 5 mL/kg IV in infants and children.
- Symptomatic hyponatremia: hypertonic saline, commonly 3% saline 3 mL/kg IV, with further correction guided by sodium level and clinical response.
- Consider calcium for symptomatic hypocalcemia, and give a toxin-specific antidote where indicated, such as pyridoxine for suspected isoniazid poisoning.
- Treat hyperthermia, but do not assume that fever alone explains prolonged seizures.
2. First-line therapy: benzodiazepine at 5-10 minutes
Give one full, weight-appropriate benzodiazepine dose promptly. If seizures persist, a second dose may be given after about 5 minutes.
Important: Count benzodiazepines already given by caregivers, EMS, or another facility. In general, avoid giving more than two total adequate benzodiazepine doses before proceeding to second-line therapy, because repeated doses raise the risk of respiratory depression without reliably ending established SE.
Preferred options
| Drug and route | Typical pediatric dose | Notes |
|---|---|---|
| Lorazepam IV/IO | 0.1 mg/kg, maximum 4 mg/dose | Preferred when IV/IO access is already available. May repeat once after 5 min. |
| Midazolam IM, IN, buccal | 0.2 mg/kg, often maximum 10 mg/dose | Best practical option when IV access is delayed. IM midazolam is a strong prehospital option. |
| Diazepam IV | 0.15-0.2 mg/kg, maximum 10 mg/dose | Alternative if lorazepam unavailable. |
| Diazepam rectal | 0.5 mg/kg | Useful in community or prehospital rescue plans when other routes unavailable. |
The evidence supports IV lorazepam, IV diazepam, and IM midazolam as first-line choices. Route matters more than waiting for a preferred drug: use a non-IV route immediately if access is not available.
3. Established SE: second-line loading therapy at 10-20 minutes
If seizures persist after adequate benzodiazepine treatment, load one longer-acting antiseizure medication without delay. Start it ideally by 10 minutes and no later than about 20 minutes after recognized SE.
Main choices
| Medication | Pediatric loading dose | Key advantages | Major cautions |
|---|---|---|---|
| Levetiracetam IV/IO | 60 mg/kg, maximum 4,500 mg, over about 5-10 min | Few hemodynamic effects, minimal interactions, simple administration | Adjust maintenance dosing in renal impairment; agitation/behavioral effects can occur later |
| Fosphenytoin IV/IO | 20 mg phenytoin equivalents (PE)/kg; maximum varies by protocol, commonly 1,200-1,500 mg PE, over 10-20 min | Useful for focal-onset seizures | ECG and blood-pressure monitoring. Avoid or use specialist guidance in significant conduction disease, hypotension, and some arrhythmias |
| Phenytoin IV | 20 mg/kg at no faster than 1 mg/kg/min in children | Alternative where fosphenytoin unavailable | Extravasation/tissue injury, hypotension, dysrhythmia; use a dedicated line and monitoring |
| Valproate IV | 40 mg/kg, maximum 3,000 mg, often over 5-10 min | Minimal cardiorespiratory depression; useful alternative | Avoid or seek specialist advice in significant hepatic disease, suspected mitochondrial disorder such as POLG-related disease, urea-cycle disorder, pancreatitis, or severe thrombocytopenia |
| Phenobarbital IV | 20 mg/kg, usually over 10-20 min | Often useful in infants or when other choices unsuitable | Respiratory depression and hypotension, especially after benzodiazepines; be ready to ventilate |
Which second-line drug?
There is no single universally superior agent. In the ESETT trial, in children with benzodiazepine-refractory convulsive SE, seizure cessation within 60 minutes occurred in approximately:
- 52% with levetiracetam
- 49% with fosphenytoin
- 52% with valproate
Thus, select according to seizure type, comorbidities, contraindications, available access, and local protocol. The pediatric convulsive SE review summarizes these trial results and doses.
Practical selection:
- Levetiracetam is often favored when cardiovascular stability, drug interactions, or fast administration are priorities.
- Fosphenytoin/phenytoin may be useful for focal seizures, but needs cardiac monitoring.
- Valproate is reasonable when hepatic and metabolic contraindications have been excluded.
- Phenobarbital is commonly considered in young infants, and in some resource settings or etiologies.
4. Refractory status epilepticus: about 20-40 minutes
Definition
Refractory SE (RSE) is persistent clinical or electrographic seizure activity after:
- An adequate benzodiazepine, and
- An adequate second-line antiseizure-medication load.
At this point:
- Activate pediatric ICU/neurocritical care and pediatric neurology.
- Prepare for or proceed with intubation if ventilation, airway protection, or anesthetic treatment requires it.
- Start continuous EEG (cEEG) as early as possible. Clinical movements can stop while electrographic seizures persist, especially after neuromuscular blockade or deep sedation.
- Continue maintenance antiseizure therapy while using anesthetic treatment.
Common anesthetic approaches
| Treatment | Typical approach | Monitoring/issues |
|---|---|---|
| Midazolam infusion | Often a 0.1-0.2 mg/kg IV bolus, then 0.05-0.2 mg/kg/hour, titrated to electrographic seizure control | Hypotension, respiratory depression, tachyphylaxis |
| Pentobarbital infusion | Commonly 5-15 mg/kg loading, then 0.5-5 mg/kg/hour, titrated by cEEG | Intubation/ventilation required; hypotension, immunosuppression, ileus, prolonged sedation |
| Propofol | May be used in selected intubated children under PICU guidance | Limit duration and dose; monitor for propofol infusion syndrome, especially with prolonged or high-dose exposure |
| Ketamine | Increasingly used in refractory/super-refractory SE, typically with an IV bolus followed by infusion under specialist direction | Evidence is less certain; can be useful when GABAergic anesthetics have failed |
The endpoint is electrographic seizure cessation. Many centers maintain seizure control for roughly 24-48 hours before cautiously reducing anesthetic infusions, guided by cEEG and the underlying cause.
Recent evidence may change details of refractory drug selection: a 2024 systematic review/meta-analysis of ketamine in pediatric SE is indexed as PMID 38881333, but pediatric comparative evidence remains limited.
5. Diagnostic workup, done in parallel
Do not postpone treatment while completing investigations.
Immediate bedside and laboratory studies
- Point-of-care glucose
- CBC
- Electrolytes: sodium, potassium, bicarbonate, calcium, magnesium, phosphate
- Renal and liver function
- Blood gas and lactate if severely ill or prolonged convulsions
- Antiseizure drug concentrations if already prescribed relevant medications
- Toxicology testing when exposure is possible
- Acetaminophen/salicylate levels if intentional or uncertain ingestion is possible
- Blood cultures and inflammatory/infectious studies if sepsis or CNS infection is suspected
- Pregnancy test in postmenarchal adolescents
Cause-directed assessment
Obtain history from caregivers/EMS while treatment proceeds:
- Fever or recent infection
- Trauma or concern for nonaccidental injury
- Known epilepsy and missed medication doses
- Ingestion or access to toxins/drugs
- Metabolic disease, diabetes, renal/hepatic disease
- Developmental regression or prior neurologic symptoms
- Immunization/travel/exposure history where relevant
- Family history of epilepsy, metabolic disease, or sudden unexplained death
Neuroimaging
- Urgent noncontrast CT head if trauma, focal neurologic deficit, persistent altered consciousness, signs of raised intracranial pressure, shunt concern, suspected hemorrhage, or need to rapidly exclude a structural emergency.
- MRI brain, preferably with an epilepsy-oriented protocol, when stable, particularly for new-onset SE, focal findings, unexplained RSE, encephalitis concern, or abnormal CT.
Lumbar puncture
Perform after stabilization when CNS infection or encephalitis is suspected and there is no contraindication such as clinical concern for raised intracranial pressure, major coagulopathy, or cardiorespiratory instability. Obtain CSF cell count, glucose/protein, Gram stain/culture, and targeted PCR testing, particularly for HSV when encephalitis is possible. Start empiric antimicrobials/acyclovir promptly when indicated rather than waiting for LP.
EEG
- Obtain urgent EEG if consciousness does not recover as expected, seizures may be nonconvulsive, paralysis/sedation obscures motor activity, or RSE is present.
- cEEG is strongly indicated during anesthetic infusions and refractory SE.
If new-onset refractory SE
Consider an expanded evaluation, directed by neurology/PICU:
- Viral, bacterial, fungal, or autoimmune encephalitis testing
- Autoimmune epilepsy/encephalitis antibodies in serum and CSF
- Metabolic testing: ammonia, ketones, amino/organic acids, lactate/pyruvate when appropriate
- Genetic/metabolic consultation in infants or unexplained recurrent/refractory cases
- Screening for FIRES/NORSE in the appropriate clinical setting
Avoidable errors
- Waiting past 5 minutes to treat.
- Underdosing benzodiazepines.
- Repeating small benzodiazepine doses instead of moving to a full second-line load.
- Delaying second-line therapy for IV access, tests, imaging, or specialist arrival.
- Treating apparent clinical cessation as resolution without EEG in sedated, paralyzed, or encephalopathic children.
- Missing glucose, sodium, calcium, toxin, infection, trauma, and medication nonadherence as causes.
The broad approach is supported by the pediatric SE management review and the ESETT-focused pediatric review.
This is a shared conversation. Sign in to Orris to start your own chat.